HB 912 proposes creating a new secure forensic facility in Montana, overseen by the Department of Public Health and Human Services. This facility would provide care, treatment, and security for up to 70 individuals involved in the legal system due to mental illness, including those needing competency restoration or forensic evaluations. The bill allocates $60 million from the Behavioral Health System for Future Generations Fund to plan, construct, and equip this facility, while also expanding the fund's uses to support new behavioral health infrastructure.
HB 888 revises the powers of local boards of health concerning isolation and quarantine orders. This bill prohibits local boards of health from requiring individuals to receive a vaccination or other medication as a condition for release from an isolation or quarantine order. It amends existing state law (Section 50-2-116, MCA) that outlines the duties of these boards. The legislation also includes an appropriation.
HB 891 grants the Office of Inspector General (OIG) within the Department of Public Health and Human Services (DPHHS) new authority. This bill allows the OIG to issue subpoenas to compel the production of financial records, documents, and data. These subpoenas are specifically for investigations into waste, fraud, or abuse within health care services and public assistance programs administered by the DPHHS. The measure specifies that both the DPHHS director and the inspector general must sign these subpoenas. It also appropriates $5,000 to the DPHHS for the biennium beginning July 1, 2025, to implement these provisions.
SB 535 revises laws related to experimental treatments, primarily by requiring experimental treatment centers to obtain a license from the state department. These centers must adhere to operational standards and pay licensing fees. The bill also mandates that licensed centers allocate 2% of their net annual profits to support access to experimental treatments for qualifying Montana residents. This allocation can be fulfilled by providing free treatment or contributing to a new Insurance Premium Support Account. This account is established to help fund health insurance premiums for eligible Montana residents who purchase insurance on the federal marketplace and meet specific income criteria.
HJ 35 is a joint resolution from the Montana Legislature urging federal officials to modify current federal land management and wildfire policies. It calls for an aggressive initial attack on wildfires across all federal lands and for federal forest roads to remain open for access and fire suppression. The resolution also recommends that EPA air quality standards include wildfire smoke and that federal "let it burn" policies be reversed, ensuring NEPA processes are followed. Finally, it advocates for increased involvement of state and local governments and stakeholder groups in federal fire management decisions to protect Montana's communities.
HB 476 establishes a grant program to fund the installation and maintenance of newborn safety devices. The Department of Public Health and Human Services will award competitive grants, up to $20,000 per applicant, to eligible fire departments, hospitals, and law enforcement agencies. The department is also responsible for creating rules for the application process and evaluation criteria. The bill appropriates $160,000 from the general fund for this program, which is effective July 1, 2025, and terminates on June 30, 2027.
Senate Bill 495 eliminates the Tobacco Prevention Advisory Board. The bill repeals the specific section of law that established this board. It also amends existing statute to remove the board from the list of entities funded by state special revenue accounts, which are primarily used for tobacco disease prevention programs and the Children's Health Insurance Program. The direct effect is the dissolution of the advisory board, which previously provided guidance for these programs.
HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.
